Survey Among Healthcare Professionals Treating Patients With Metastatic Breast Cancer in Selected European Countries to Evaluate Their Knowledge on Management of Hyperglycemia When Using Alpelisib

Survey Among Healthcare Professionals Treating Patients With Metastatic Breast Cancer in Selected European Countries to Evaluate Their Knowledge on Management of Hyperglycemia When Using Alpelisib

ClinicalTrials.gov Identifier: NCT05073120

Novartis Reference Number: CBYL719C2005

Last Update: Mar 23, 2022

See if you pre-qualify

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. 

Study Description

This is a multinational, non-interventional, cross-sectional survey conducted among HCPs based in the EU/EEA who prescribe Piqray. The survey will assess the knowledge of HCPs prescribing Piqray in relation to the management of hyperglycemia in patients treated with Piqray. The survey will endeavor to collect a minimum to 30-50 completed surveys.

Condition 
Breast Cancer
Phase 
Not Given
Overall status 
Recruiting
Start date 
Feb 28, 2022
Completion date 
Sep 05, 2022
Gender 
All
Age(s)
18 Years and older (Adult, Older Adult)

Interventions

Other
Piqray Prescriber's/HCP guide for hyperglycemia
oncologists/healthcare professionals (HCPs) prescribing Piqray in the EU/EEA will be provided with the Piqray Prescriber's/HCP Guide for hyperglycemia (educational material). The educational material aims to provide oncologists/HCPs prescribing Piqray with additional measures/guidance prior to, and during treatment with Piqray for the identification and management of hyperglycemia.
Other
Piqray Prescriber's/HCP guide for hyperglycemia
oncologists/healthcare professionals (HCPs) prescribing Piqray in the EU/EEA will be provided with the Piqray Prescriber's/HCP Guide for hyperglycemia (educational material). The educational material aims to provide oncologists/HCPs prescribing Piqray with additional measures/guidance prior to, and during treatment with Piqray for the identification and management of hyperglycemia.
Other
Piqray Prescriber's/HCP guide for hyperglycemia
oncologists/healthcare professionals (HCPs) prescribing Piqray in the EU/EEA will be provided with the Piqray Prescriber's/HCP Guide for hyperglycemia (educational material). The educational material aims to provide oncologists/HCPs prescribing Piqray with additional measures/guidance prior to, and during treatment with Piqray for the identification and management of hyperglycemia.
Other
Piqray Prescriber's/HCP guide for hyperglycemia
oncologists/healthcare professionals (HCPs) prescribing Piqray in the EU/EEA will be provided with the Piqray Prescriber's/HCP Guide for hyperglycemia (educational material). The educational material aims to provide oncologists/HCPs prescribing Piqray with additional measures/guidance prior to, and during treatment with Piqray for the identification and management of hyperglycemia.
Other
Piqray Prescriber's/HCP guide for hyperglycemia
oncologists/healthcare professionals (HCPs) prescribing Piqray in the EU/EEA will be provided with the Piqray Prescriber's/HCP Guide for hyperglycemia (educational material). The educational material aims to provide oncologists/HCPs prescribing Piqray with additional measures/guidance prior to, and during treatment with Piqray for the identification and management of hyperglycemia.

Eligibility Criteria

Inclusion Criteria:

Has prescribed Piqray to at least 1 locally advanced or MBC patient within 6 months prior to completing the survey.
Provides permission to share their anonymized responses in aggregate with EMA or NCAs, if requested.

Exclusion Criteria:

HCPs who are direct employees of Novartis, the EMA (or any other regulatory bodies), or ICON.

Study Locations

Switzerland
Novartis Investigative Site
Recruiting
Basel,
-
Switzerland
Novartis Investigative Site
Recruiting
Basel,
-
Switzerland
Novartis Investigative Site
Recruiting
Basel,
-
Switzerland
Novartis Investigative Site
Recruiting
Basel,
-
Switzerland
Novartis Investigative Site
Recruiting
Basel,
-
Switzerland

Contacts

Name: 
Novartis Pharmaceuticals
Phone: 
+41613241111
Email: 
[email protected]
Name: 
Novartis Pharmaceuticals
Phone: 
+41613241111
Email: 
[email protected]
Name: 
Novartis Pharmaceuticals
Phone: 
+41613241111
Email: 
[email protected]
Name: 
Novartis Pharmaceuticals
Phone: 
+41613241111
Email: 
[email protected]
Name: 
Novartis Pharmaceuticals
Phone: 
+41613241111
Email: 
[email protected]

Have a question?

Call 1-888-669-6682 or email [email protected]